Slide 1

##Epigenetics

Slide 2

##Background

Psychosis – symptoms in SCZ, BPD and MDD – including non specificed

AP drugs

Slide 3

## Background

AP drugs – first line of treatment for psychosis

* Believed to work on neurotransmitter systems

- Efficient for hallucinations but less so for cognitive

The focus of SCZ research has been on the dysfunction thought to underlie changes in network activity across the brain – in particular, the balance between excitatory and inhibitory signaling. Glutamate (excitatory). GABA (inhibitory)

Slide 4

##GWAS findings

Slide 5

##EWAS findings – WHAT are they

Slide 6

## Hypothesize

Common and specific

We hypothesize that differential DNA methylation associated with

AP drugs identified in the peripheral blood of individuals taking these drugs, independent of diagnosis

Slide 7

## Factors that influence the efficacy of AP

Age: Significant impact on drug concentrationmost studies show increased concentration above age 60, but some, like Olanzapine and Quetiapine show changes every 5 to 10 years.

Sex: Women generally have dose-adjusted concentrations 20-30% higher than men (Castberg et all, 2017)

- Age, gender, smoking <br> <br />

- Genotype - i.e. metabolic enzymes <br> <br />

- Polypharmacy <br> <br />

- Time of day of administration <br> <br />

- Dose & Compliance - as monitored by serum values

Slide 8

## TOP Cohort

Slide 9

## Study/model design

Slide 10

### Models selected for Quetiapine n=92

Slide 11

### Results for CpGs at Genome-wide significance

Slide 12

## Manhatten plots comparing the two models

Slide 13

### Glycosylation

Regulates nearly all cellular processes

Glycans are necessary for proper protein folding, protein trafficking, cell-cell recognition, cell migration, etc. Gysosulation enzymes often function in a single pathway with only one or occasional a few enzymes capable of completing each step.

Slide 14

### Disregulated glycosylation in SCZ

Presynaptic neuron in green, postsynapitic neuron in blue

In addition to genes involved in synaptic transmission and the immune system, several glycosulation enzymes are directly implicated in the pathogenesis of the disorder (Mealer, 2020)

Glycosulation may contribute to abnormal neuronal signaling and connectivity observed in SCZ. However, such changes may also results from exposures associated with the disease ((Williams, 2020)

Slide 15

Glycosylation changes observed in SCZ span several brain regions, cellular pathways, classes of proteins, and steps of the synthetic pathway. This suggests a general dysregulation of glycosylation as a feature of the disease state and does not implicated a specific synthetic step or cell type as being uniquely vulnerable.

Articles in psychiatry. Williams and Mealer

Slide 16

### GLT8D1 <br> - transcripts associated with SCZ and BPD

Slide 17

Differentially Methylated Regions (DMRs) <br/>

Slide 18

### Future prospects

Slide 19

##Acknowledgements